Open contest
5 companies value 140 bn revenue 21 bn margin 19.2% free cash flow 3.8 bn avg. score 4.9
ARGX holds 36.5% of the group's value, 1.6x the runner-up · ALNY leads the industry without being the largest
| Rank | Ticker | Company | Share | Value | Revenue | Margin | FCF | 5 years | FCF/px | Yield | What it does · why it is here |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARGX | argenx Netherlands · score 5.2 | 37% | 51 bn | 5.3 bn | 32.2% | 1.0 bn | 1.9% | — | Antibodies for autoimmune diseases, from the Netherlands · Antibodies for autoimmune diseases, with a highly successful launch | |
| 2 | ALNY | Alnylam Pharmaceuticals United States · score 5.6 | 22% | 31 bn | 4.8 bn | 16.1% | 0.8 bn | 2.6% | — | RNA interference medicines · Pioneer and leader in RNA interference therapies | |
| 3 | INCY | Incyte United States · score 7.1 | 16% | 23 bn | 5.8 bn | 27.7% | 2.0 bn | 8.6% | — | Biopharma in oncology and dermatology · Established franchise in oncology and dermatology | |
| 4 | INSM | Insmed United States · score 0.0 | 15% | 21 bn | 1.1 bn | -76.9% | -0.8 bn | -3.9% | — | Biopharma in rare lung diseases · Therapies for rare lung diseases | |
| 5 | NBIX | Neurocrine Biosciences United States · score 6.7 | 10% | 14 bn | 3.4 bn | 20.9% | 0.9 bn | 6.3% | — | Neuroscience biopharma, with Ingrezza · Leader in neurology and movement disorders |
Other industries in the same sector
- Sector overview
- Large-cap pharmaceuticals 9 companies
- Biotechnology 57 companies
- European pharmaceuticals 5 companies
- Lab tools and consumables 37 companies
- Health insurance and services 17 companies
- Medical devices 87 companies
- Specialty pharmaceuticals 77 companies
- Pharmaceutical distribution 7 companies
- Clinical-stage pharmaceuticals 251 companies
- Robotic surgery and advanced medtech 9 companies
- Hospitals 23 companies
- Molecular testing and advanced diagnostics 42 companies
and 22 industries more
- Vaccines and mRNA 14 companies
- Clinical-stage biotech 200 companies
- Generics and biosimilars 10 companies
- Animal health 7 companies
- Contract research (CRO) 10 companies
- Consumer health (OTC) 4 companies
- Healthcare software 18 companies
- Rehabilitation and home care 15 companies
- Genomics and sequencing 9 companies
- Structural heart 8 companies
- Ophthalmology 12 companies
- Medical imaging and hospital equipment 16 companies
- Diagnostic labs 6 companies
- Medical and dental supply distribution 3 companies
- Diabetes monitoring 9 companies
- Pharmaceutical royalties 5 companies
- Respiratory and sleep therapy 9 companies
- Orthopedic implants 17 companies
- Dialysis 3 companies
- Telehealth and digital health 12 companies
- Dental 4 companies
- Medical and recreational cannabis 16 companies
What this is. A catalogue, not a guide. Every industry with stocks listed on the NYSE or NASDAQ, the companies contending for its leadership, what each one does according to its own annual report, and the balance sheet it filed with the SEC.
The score runs from 0 to 10 and compares each company with every other one in the almanac on cash generation, profitability, debt, dividends and consistency over the last five years. The higher it is, the better the company fares in that comparison. Curious how much each part weighs? Ask at the bottom of the page.
The score runs from 0 to 10 and compares each company with every other one in the almanac on cash generation, profitability, debt, dividends and consistency over the last five years. The higher it is, the better the company fares in that comparison. Curious how much each part weighs? Ask at the bottom of the page.